What is Schisandrin B and where does it come from?

Schisandrin B is a dibenzocyclooctadiene lignan—a type of polyphenolic plant compound—isolated from the dried fruits of Schisandra chinensis, a vine berry used for over 2,000 years in Traditional Chinese Medicine. It is one of the most pharmacologically active of several structurally related lignans in the fruit, alongside Schisandrin A and C, and is extracted via solvent-based chromatographic methods for research and supplement production. The parent plant is native to northeastern China, Korea, and the Russian Far East.

Does Schisandrin B have proven anticancer effects in humans?

No human clinical trials have been conducted on isolated Schisandrin B for cancer treatment. Evidence is limited to preclinical studies: in vitro experiments in colon cancer cell lines (HCT116, HT29, SW620) at 5–50 µM concentrations demonstrated apoptosis induction and proliferation inhibition, while mouse xenograft models showed tumor growth suppression comparable to 5-fluorouracil. These results are hypothesis-generating and cannot be directly extrapolated to human therapeutic efficacy or safety.

How does Schisandrin B protect the liver?

Schisandrin B supports liver health primarily through its antioxidant mechanisms: it upregulates hepatic superoxide dismutase, glutathione, glutathione-S-transferase, glutathione reductase, and glucose-6-phosphate dehydrogenase activity, collectively reducing oxidative stress-driven hepatocellular damage. It also reduces malondialdehyde accumulation and lactate dehydrogenase leakage, markers of lipid peroxidation and membrane injury respectively. These effects have been demonstrated in animal and cell-based models; human hepatoprotective clinical trials for isolated Sch B have not been published.

What is the recommended dose of Schisandrin B?

No standardized human dose for isolated Schisandrin B has been established, as no clinical trials have defined a safe and effective dose range. Preclinical studies used concentrations of 5–50 µM in cell culture systems, which do not directly translate to oral supplement doses due to unknown bioavailability. Traditional TCM preparations use 1.5–9 g per day of whole dried Schisandra chinensis fruit as decoction, but Schisandrin B content in such preparations is variable and unstandardized.

Is Schisandrin B safe to take with medications?

Specific drug interaction data for isolated Schisandrin B is not available in published literature. However, Schisandra chinensis whole extract is a documented modulator of CYP3A4 and P-glycoprotein drug metabolism pathways, suggesting Schisandrin B may potentially alter the plasma levels of medications processed by these enzymes—including immunosuppressants like tacrolimus, antiretrovirals, and certain chemotherapy agents. Until human pharmacokinetic and drug interaction studies are completed, individuals on prescription medications should consult a healthcare provider before using Schisandrin B or Schisandra extracts.

What forms of Schisandrin B supplementation are most bioavailable?

Schisandrin B is a lipophilic compound, so it is better absorbed when taken with dietary fats or in lipid-based delivery systems such as softgels or standardized extracts with oil carriers. Standardized extracts of Schisandra chinensis that guarantee minimum Schisandrin B content (typically 9% or higher) show more consistent bioavailability than whole-berry powders, which may have highly variable lignan levels depending on growing conditions and processing methods.

Who benefits most from Schisandrin B supplementation?

Individuals with elevated liver enzyme markers, chronic oxidative stress, or those taking hepatotoxic medications (such as chemotherapy or antiretrovirals) may benefit most from Schisandrin B's hepatoprotective and antioxidant properties. It is also traditionally used to support stress resilience and endurance in athletes and individuals with high physical or mental demands, though human clinical evidence for these adaptogenic benefits is more limited than for liver protection.

How does Schisandrin B compare to other liver-protective compounds like milk thistle?

Schisandrin B and milk thistle (silymarin) both support liver health through antioxidant mechanisms, but Schisandrin B specifically upregulates phase II detoxification enzymes like glutathione-S-transferase and superoxide dismutase, while silymarin functions primarily as a direct free radical scavenger and anti-inflammatory. Schisandrin B has stronger evidence in traditional use for hepatic protection in Asian medicine, whereas milk thistle has more Western clinical trials; they may have complementary mechanisms if used together, though direct comparative studies are limited.

Schisandrin B

Schisandrin B is a dibenzocyclooctadiene lignan that induces apoptosis in cancer cells by upregulating BAX and cleaved caspase-3 while suppressing BCL-2, and exerts antioxidant effects by boosting superoxide dismutase, glutathione, and glutathione-S-transferase activity more potently than vitamin C at equivalent concentrations. In preclinical colon cancer xenograft models, Sch B suppressed tumor growth at 5–50 µM concentrations with IC50 values confirmed by CCK-8 assay, and produced tumor necrosis and reduced inflammatory infiltration comparable to the chemotherapeutic agent 5-fluorouracil.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Schisandrin B (Sch B) is a dibenzocyclooctadiene lignan isolated primarily from the dried fruits of Schisandra chinensis, a woody vine native to forests of northeastern China, the Russian Far East, and Korea, where it thrives in cool, moist, semi-shaded mountain environments. The plant has been cultivated in China for centuries, particularly in Liaoning, Jilin, and Heilongjiang provinces, where the berries—called 'Wu Wei Zi' (five-flavor fruit) in Traditional Chinese Medicine—are harvested in autumn. Schisandrin B is one of several closely related lignans in the fruit, alongside Schisandrin A and Schisandrin C, and is typically isolated via solvent extraction and chromatographic purification for pharmacological research.

Historical & Cultural Context

Schisandra chinensis, the botanical source of Schisandrin B, has been documented in Traditional Chinese Medicine for over 2,000 years under the name Wu Wei Zi ('five-flavor fruit'), referencing its simultaneous sour, sweet, bitter, salty, and pungent taste profile attributed to its complex lignan and organic acid chemistry. Classical TCM texts prescribe Wu Wei Zi for liver and kidney tonification, astringing lung qi to relieve chronic cough, calming the heart-spirit to treat insomnia and palpitations, and preserving essence—a broad adaptogenic profile that predates modern understanding of its isolated lignans. Russian and Soviet-era researchers studied Schisandra extensively in the mid-20th century as an adaptogen for military and athletic endurance applications, though this work focused on the whole fruit rather than isolated Schisandrin B. The isolation and characterization of Schisandrin B as a distinct pharmacologically active lignan is a product of modern analytical chemistry, with systematic investigation of its molecular mechanisms emerging primarily in the late 20th and early 21st centuries.

Health Benefits

- **Hepatoprotection**: Sch B has been extensively studied for liver protection through its antioxidant upregulation of glutathione-S-transferase and superoxide dismutase, reducing oxidative hepatocellular damage; traditional use of Schisandra chinensis in TCM is largely rooted in this hepatoprotective effect.
- **Antioxidant Activity**: Sch B scavenges hydroxyl radicals and reduces malondialdehyde and reactive oxygen species more effectively than vitamin C at equivalent molar concentrations, acting as a potent non-enzymatic and enzymatic antioxidant by stimulating G6PD and glutathione reductase activity.
- **Anticancer (Preclinical)**: In colon cancer cell lines HCT116, HT29, and SW620, Sch B inhibits proliferation and induces apoptosis in a concentration-dependent manner, with cellular uptake increasing from 17% at baseline to 42% (approximately 5.83 pg/cell) after 48 hours of treatment.
- **Anti-inflammatory Effects**: Sch B downregulates pro-inflammatory gene targets including IL13 and HSPA12B, reducing inflammatory signaling cascades linked to tumor microenvironment promotion and systemic inflammatory states.
- **Cardioprotection**: Sch B is reported to protect cardiomyocytes from oxidative injury by reducing lactate dehydrogenase leakage and MDA accumulation, supporting mitochondrial membrane integrity under ischemic or toxic stress conditions.
- **Neuroprotection**: Preclinical evidence suggests Sch B attenuates neuronal oxidative stress and may modulate pathways relevant to cognitive aging, consistent with the broader adaptogenic profile of Schisandra chinensis in traditional anxiolytic and anti-aging applications.
- **Cell Cycle Arrest**: Molecular docking analyses demonstrate Sch B binds cyclins D, E, and A and CDKs 2 and 4 with superior affinity compared to Schisandrin A and C, promoting arrest across G1, S, and G2 phases and halting aberrant cell proliferation in cancer models.

How It Works

Schisandrin B induces apoptosis primarily by shifting the BAX/BCL-2 ratio in favor of pro-apoptotic signaling: it upregulates BAX protein expression and increases the ratio of cleaved caspase-3 to pro-caspase-3 without altering total pro-caspase-3 levels, effectively committing cells to the intrinsic apoptotic pathway in a concentration-dependent fashion. At the transcriptional level, Sch B downregulates genes including KIAA0753, IL13, HSPA12B, MGAT4B, THAP11, QSOX1, DTX4, and FBXL8, suppressing pathways governing cell motility, invasion, metastasis, drug resistance, and inflammatory immune activation. As an antioxidant, Sch B enhances enzymatic defenses—superoxide dismutase, glutathione, glutathione-S-transferase, glutathione reductase, and glucose-6-phosphate dehydrogenase—while directly scavenging reactive oxygen species and hydroxyl radicals, thereby reducing lipid peroxidation byproduct malondialdehyde and preventing lactate dehydrogenase-mediated membrane damage. Molecular docking studies confirm that Sch B exhibits superior binding affinity to cyclins D/E/A and CDK2/4 compared to structurally related lignans Schisandrin A and C, explaining its capacity to impose multi-phase cell cycle arrest alongside its pro-apoptotic signaling.

Scientific Research

The evidence base for Schisandrin B is exclusively preclinical, comprising in vitro cell line experiments and in vivo mouse xenograft models, with no published human clinical trials reported. In vitro studies using CCK-8, Trypan blue exclusion, and BrdU-ELISA assays in colon cancer lines (HCT116, HT29, SW620) at 5–50 µM concentrations have consistently demonstrated proliferation inhibition and apoptosis induction, while in vivo xenograft models showed tumor growth suppression and histological evidence of necrosis and reduced inflammatory infiltration at levels comparable to 5-fluorouracil, though Ki-67 proliferation marker changes were not statistically significant. Mechanistic reviews and molecular docking analyses support the biological plausibility of its anticancer and antioxidant effects, but the absence of pharmacokinetic data in humans, standardized dosing, and randomized controlled trials means the overall evidence quality remains at a preliminary preclinical stage. Independent validation across multiple laboratories and eventual Phase I/II human trials are required before any clinical application can be recommended.

Clinical Summary

No human clinical trials investigating Schisandrin B as an isolated compound have been published to date. Preclinical evidence demonstrates antitumor activity in colon cancer xenograft mouse models, with outcomes including reduced tumor mass, decreased cell density, histological necrosis, and inflammatory infiltrate reduction comparable to 5-FU, though Ki-67 proliferative index changes did not reach significance. Antioxidant efficacy has been quantified in cellular assays where Sch B outperformed vitamin C in hydroxyl radical scavenging at equal concentrations, and hepatoprotective effects are supported by enzyme-activity assays in animal models. Confidence in translating these results to human clinical outcomes is low given the complete absence of clinical trial data, and results should be interpreted exclusively within the context of preclinical hypothesis generation.

Nutritional Profile

Schisandrin B is a pure isolated lignan compound (molecular formula C₂₃H₂₈O₇, molecular weight approximately 432.46 g/mol) and does not contribute macronutrients, vitamins, or minerals in pharmacological doses. As an isolated compound rather than a whole-food ingredient, its 'nutritional profile' is defined by its phytochemical identity: a dibenzocyclooctadiene lignan with a methylenedioxy and methoxy-substituted aromatic ring system conferring potent antioxidant electron-donating capacity. Cellular uptake in experimental models reached approximately 5.83 pg per cell after 48 hours at 50 µM, representing roughly 42% of applied dose, though human oral bioavailability—including first-pass hepatic metabolism, plasma protein binding, and blood-brain barrier penetration—has not been formally characterized. Lipophilicity of the dibenzocyclooctadiene scaffold suggests potential for enhanced absorption with lipid-containing meals, but this has not been confirmed in human pharmacokinetic studies.

Preparation & Dosage

- **Research-Grade Extract (In Vitro)**: Concentrations of 5–50 µM used in colon cancer cell line studies; no established human equivalent dose derived from these data.
- **Standardized Schisandra Extract (Supplement Form)**: Commercial supplements typically standardize to total schisandrin content (often 1–9% schisandrins by weight); Schisandrin B content within such extracts is not consistently reported or standardized.
- **Whole Fruit Powder**: Derived from dried Schisandra chinensis berries; traditional TCM doses of the whole fruit range from 1.5–9 g per day as decoction, though Sch B bioavailability from this form is unquantified.
- **Isolated Compound (Experimental)**: Sch B is isolated via ethanol or methanol extraction followed by column chromatography; no validated oral bioavailability data in humans is currently available.
- **Timing Notes**: No clinical timing recommendations exist; preclinical protocols used continuous exposure over 24–48 hours in cell models and repeated dosing in xenograft studies without translatable human dosing schedules.
- **Standardization Caution**: Supplements labeled as 'Schisandrin B' are not uniformly standardized; purchasers should verify third-party certificates of analysis for actual Sch B content.

Synergy & Pairings

Within the Schisandra chinensis lignan family, Schisandrin B is compared favorably to Schisandrin A and C in molecular docking studies, suggesting that whole-fruit extracts containing multiple co-occurring lignans may produce complementary multi-target effects on apoptosis, cell cycle, and antioxidant pathways that isolated Sch B alone cannot fully replicate. Traditional TCM formulations pair Wu Wei Zi with hepatoprotective herbs such as Yin Chen Hao (Artemisia capillaris) and Wu Ling San for synergistic liver protection, a combination whose molecular basis may involve complementary modulation of glutathione synthesis and cytochrome P450 detoxification enzymes. In the context of oncology research, co-administration of Sch B with conventional chemotherapeutics like 5-fluorouracil in xenograft models produced comparable tumor suppression, raising the hypothesis—requiring clinical validation—that Sch B could serve as a chemosensitizer or adjunct agent.

Safety & Interactions

Schisandrin B is characterized in preclinical literature as a low-toxicity compound, with in vivo mouse xenograft studies reporting no overt signs of systemic toxicity at doses producing antitumor effects; however, formal toxicological profiling including LD50, NOAEL, and long-term chronic toxicity studies in humans are absent. No specific drug interactions have been identified for isolated Sch B, but given that Schisandra chinensis whole extract is a known modulator of cytochrome P450 enzymes (particularly CYP3A4) and P-glycoprotein, it is plausible that Sch B may share pharmacokinetic interaction potential with drugs metabolized by these pathways, including immunosuppressants, antiretrovirals, and certain chemotherapeutics. No contraindications specific to Schisandrin B have been established; however, pregnant and lactating women should avoid use given the complete absence of reproductive safety data, and individuals receiving chemotherapy should consult an oncologist before use due to potential additive or antagonistic interactions with cytotoxic agents. Maximum safe doses in humans have not been established, and any supplemental use of isolated Schisandrin B outside of a clinical research context is not currently supported by evidence.